From: [JJCUS] <[its.jnj.com]>
Sent: lundi 4 mai 2020 15:00
To: GAUER Celine (SG)
Cc: 
Subject: Re: Follow up on bilateral discussions // confidential

Dear Mrs Gauer,

Thank you for making time to meet with us. We can make ourselves available for the meeting. As we are still discussing with European partner companies (contract manufacturers) to accelerate vaccine production, we would like to discuss high level financial constructs / facilities which can support acceleration on our manufacturing capacity.
Should we prepare for a high level scientific – clinical – regulatory and manufacturing review on our COVID19 vaccine with your team as an introduction?
What is the format you prefer? do you set up a videoconference or should we do that.

Thank you very much, Looking forward seeing you on Wednesday.

Best regards,

Johnson & Johnson / Janssen

---

From: <@ec.europa.eu> on behalf of <@ec.europa.eu>
Date: Monday, 4 May 2020 at 12:30
To: "[JJCUS]" <[its.jnj.com]>
Subject: [EXTERNAL] RE: Follow up on bilateral discussions // confidential

WARNING: This email originated from outside the company. Do not click on links unless you recognize the sender and have confidence the content is safe. If you have concerns about this email, send it as an attachment to ‘SuspiciousEmail@ITS.JNJ.COM’.

Dear [Name],

Mrs Gauer asked me to thank you for your email.
We propose to schedule the skype meeting on the 6th May at 16h30. Could you please inform us whether this timing is convenient for you? Once confirmed, I’ll send you the outlook calendar invitation with the link for connection.

I remain at your disposal for any further information you may require

Kind regards

Celine Gauer – Deputy Secretary General
European Commission – Secretariat General
BERL 13/
B-1049 Brussels
Tel.: 
Email: @ec.europa.eu

From: [JJCUS] <@its.inj.com>
Sent: Thursday, April 30, 2020 5:12 PM
To: GAUER Celine (SG) <@ec.europa.eu>; VANDENBERGHE Kurt (CAB-VON DER LEYEN) <@ec.europa.eu>
Cc: [JACDE] <@its.inj.com>; [JRDBE] <@its.inj.com>
Subject: Follow up on bilateral discussions // confidential

Dear Mrs Gauer and Mr Vandenberghe,

As a short follow up our industry meeting on Tuesday and our call earlier this morning, I wanted to confirm the interest of Janssen/J&J for a bilateral discussion.

The reason to have the discussion sooner than later is to be ready with sufficient Covid-19 vaccines when clinical data are expected later this year or early next year. We have a goal on providing more than [redacted] Covid-19 vaccines to the world in 2021 under emergency use conditions. Expanding our production capacity cannot wait for the global multilateral discussion and decision on financing and commitment. It will delay availability of vaccines in Europe and ROW, by several months if not years. It takes 8-12 months to adapt production plants, install the right equipment, hire the expert people, and transfer vaccine technology and validate the production batches from a new plant.

Over the last 7 days, we announced 2 collaborations (see included link) [redacted] expanding our capacity for Covid-19 vaccine production to deliver [redacted] million vaccines in 2021. The tech transfer is starting now to enable delivery [redacted]. See below the press coverage.
While we have currently production capacity for Covid-19 vaccines available in [redacted], we are working on a similar scenario for Europe looking to increase available annual capacity [redacted]. We are discussing [redacted] and are exploring [redacted] developing world.

Based on our experience with our vaccine platform and currently available data on Covid-19 vaccine candidate, we are committed to move forward starting to contract/build additional capacity. We would very much appreciate to have the opportunity to address potential ways to collaborate in a first bilateral discussion.

We will connect early next week to plan for a meeting.

Thank you for your commitment and best regards,

Vice Chairman & CSO
Johnson & Johnson